• Peer-reviewed study demonstrates sustained pain reduction, improved function, and potential disease-modifying effects of PPS in naturally occurring canine osteoarthritis
• Findings align with Paradigm's human Phase 2 data, providing translational validation and insight into longer-term outcomes
• Strengthens scientific and regulatory foundation for Paradigm's ongoing Phase 3 iPPS program

Paradigm Biopharmaceuticals Ltd. has announced the publication of a peer-reviewed manuscript in PLOS One, evaluating the durability and potential disease-modifying effects of a six-week course of subcutaneous PPS in companion dogs with naturally occurring osteoarthritis. The study, conducted in collaboration with the University of Melbourne, demonstrated sustained reductions in chronic pain, normalization of gait symmetry, and stabilization of cartilage volume in PPS-treated dogs compared to placebo over a 26-week follow-up period. Biomarker changes were consistent with slowed cartilage degradation and altered bone and cartilage turnover following PPS treatment. Unlike surgically induced or laboratory-based models, this study evaluated PPS in a naturally occurring, spontaneously developing osteoarthritis setting, closely reflecting the biological, mechanical, and inflammatory drivers of human disease. The 26-week follow-up period is considered broadly analogous to multiple years of disease progression in people, providing a compressed, real-world translational view of longer-term outcomes. The findings align closely with outcomes observed in Paradigm's Phase 2 human studies, strengthening the scientific and regulatory foundation supporting the company's ongoing Phase 3 iPPS program.